Condition
Atypical Lobular Hyperplasia
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Completed2
Not Yet Recruiting1
Withdrawn1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02928978Phase 2Completed
Ruxolitinib for Premalignant Breast Disease
NCT07499999Phase 2Not Yet Recruiting
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT03868475Not ApplicableWithdrawn
Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions
NCT05868252Unknown
Molecular Analysis of the Sloane Project
NCT00620087Not ApplicableCompletedPrimary
Molecular Breast Imaging in Women With Atypia and LCIS
Showing all 5 trials